Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Announces Positive Outcome of Interim Analysis of Phase 2 Randomized Trial in First Line Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"DENMARK","productType":"Peptide","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Announces Late-Breaking Oral Presentation of Phase 2 Clinical Melanoma Data Including Complete Response (CR) Rate of 45 Percent","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"DENMARK","productType":"Peptide","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Grabs Breakthrough Therapy Designation for IO102 and IO103 in Combination with Anti-PD-1 in Unresectable\/ Metastatic Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"IO Biotech","sponsor":"HBM Healthcare Investment","pharmaFlowCategory":"D","amount":"$153.9 million","upfrontCash":"Undisclosed","newsHeadline":"IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Announces Acceptance of Abstract to be Presented at AACR Annual Meeting on April 8, 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Announces Presentation of New Data from MM1636 Phase 1\/2 Clinical Trial Presented at 2022 AACR Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Merck & Co","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Announces Initiation of Phase 2 Trial of IO102-IO103 in Combination With KEYTRUDA (pembrolizumab) as First-Line Treatment in a Multi-Arm Basket Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA (pembrolizumab) as First-Line Treatment in Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Announces Two Presentations at the American Society of Clinical Oncology Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancer\u2019s (SITC) 37th Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Merck & Co","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA\u00ae (pembrolizumab) in a Phase 2, Multi-cohort Trial in Patients with Resectable Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Peptide","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Lundbeckfonden BioCapital","pharmaFlowCategory":"D","amount":"$75.0 million","upfrontCash":"Undisclosed","newsHeadline":"IO Biotech, Inc. Announces $75 Million Private Placement Financing","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"August 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"IO Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant\/Adjuvant Solid Tumor Basket Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"DENMARK","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by IO Biotech

    Menu

    IO Biotech

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              IO Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

              Details:

              IO102-IO103 is an off-the-shelf, cancer vaccine designed to kill both tumor cells and immune-suppressive cells. It is under phase 2 clinial trials in combination with pembrolizumab for the treatment of resectable melanoma or squamous cell carcinoma of the head and neck.

              Lead Product(s): IO102,IO103,Pembrolizumab

              Therapeutic Area: Oncology Product Name: IO102-IO103

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 21, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IO Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

              Details:

              IO102-IO103 is an investigational immune-modulating cancer vaccine designed to target the immunosuppressive mechanisms mediated by the proteins indoleamine 2,3-dioxygenase (IDO) and PD-L1.

              Lead Product(s): IO102,IO103,Pembrolizumab

              Therapeutic Area: Oncology Product Name: IO102-IO103

              Highest Development Status: Phase III Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 10, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IO Biotech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IO Biotech, Inc. Announces $75 Million Private Placement Financing

              Details:

              The net proceeds will be used for the development of IO102-IO103, an investigational immune-modulating cancer vaccine designed to target the immunosuppressive mechanisms mediated by the proteins indoleamine 2,3-dioxygenase (IDO) and PD-L1.

              Lead Product(s): IO102,IO103,Pembrolizumab

              Therapeutic Area: Oncology Product Name: IO102-IO103

              Highest Development Status: Phase III Product Type: Vaccine

              Partner/Sponsor/Collaborator: Lundbeckfonden BioCapital

              Deal Size: $75.0 million Upfront Cash: Undisclosed

              Deal Type: Private Placement August 07, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IO Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial at University of California Davis Comprehensive Cancer Center

              Details:

              IO102-IO103 is an investigational immune-modulating cancer vaccine designed to target the immunosuppressive mechanisms mediated by the proteins indoleamine 2,3-dioxygenase (IDO) and PD-L1.

              Lead Product(s): IO102,IO103,Pembrolizumab

              Therapeutic Area: Oncology Product Name: IO102-IO103

              Highest Development Status: Phase III Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable July 28, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IO Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone

              Details:

              IO102-IO103 is an investigational immune-modulating cancer vaccine designed to target the immunosuppressive mechanisms mediated by the key immunosuppressive proteins indoleamine 2,3-dioxygenase (IDO) and PD-L1 with melanoma patients.

              Lead Product(s): IO102,IO103,Pembrolizumab

              Therapeutic Area: Oncology Product Name: IO102-IO103

              Highest Development Status: Phase III Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IO Biotech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IO Biotech Announces New Clinical Collaboration with Merck to Evaluate Neoadjuvant and Adjuvant IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) in a Phase 2, Mul...

              Details:

              Under the terms of the agreement, IO Biotech will sponsor the Phase 2 trial and Merck will supply pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103.

              Lead Product(s): IO102-IO103,Pembrolizumab

              Therapeutic Area: Oncology Product Name: IO102-IO103

              Highest Development Status: Phase II Product Type: Peptide

              Partner/Sponsor/Collaborator: Merck & Co

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration November 03, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IO Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IO Biotech Announces Invited Oral Presentation and Two Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting

              Details:

              IO102-IO103, combines two novel immunotherapeutics, IO102 and IO103, which are designed to target IDO and PD-L1 expressing cells, respectively. IDO and PD-L1 are often dysregulated and over-expressed in a wide range of solid tumors.

              Lead Product(s): IO102,Nivolumab

              Therapeutic Area: Oncology Product Name: IO102

              Highest Development Status: Phase I/ Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 05, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IO Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IO Biotech Announces Two Presentations at the American Society of Clinical Oncology Annual Meeting 2022

              Details:

              IO102-IO103 is an investigational cancer immunotherapy designed to target the immunosuppressive mechanisms mediated by the key proteins indoleamine 2,3-dehydrogenase (IDO) and PD-L1.

              Lead Product(s): IO102,IO103,Pembrolizumab

              Therapeutic Area: Oncology Product Name: IO102

              Highest Development Status: Phase III Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 26, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IO Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA (pembrolizumab) as First-Line Treatment in Advanced Melanoma

              Details:

              IO102-IO103 is an investigational cancer immunotherapy designed to target the immunosuppressive mechanisms mediated by the key immunosuppressive proteins indoleamine 2,3-dehydrogenase (IDO) and PD-L1.

              Lead Product(s): IO102,IO103,Pembrolizumab

              Therapeutic Area: Oncology Product Name: IO102

              Highest Development Status: Phase III Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 18, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              IO Biotech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Denmark
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IO Biotech Announces Initiation of Phase 2 Trial of IO102-IO103 in Combination With KEYTRUDA (pembrolizumab) as First-Line Treatment in a Multi-Arm Basket Trial

              Details:

              IO102-IO103, an investigational cancer immunotherapy designed to target immunosuppressive mechanisms mediated by key proteins indoleamine 2,3-dehydrogenase (IDO) and PD-L1.

              Lead Product(s): IO102-IO103,Pembrolizumab

              Therapeutic Area: Oncology Product Name: IO102-IO103

              Highest Development Status: Phase II Product Type: Small molecule

              Recipient: Merck & Co

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 12, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY